AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
- Forty students will receive $2,500 scholarships for the 2013-2014 school year
- Apply through Friday, June 14 at www.AbbVieCFScholarship.com
NORTH CHICAGO, Ill., May 1, 2013 /PRNewswire/ -- AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the AbbVie CF Scholarship for the 2013-2014 academic school year.
Previously known as the CFCareForward Scholarship, the AbbVie CF Scholarship was established 21 years ago to honor young adults with CF as they pursue goals of higher education. In 2013, forty students will be awarded $2,500 each based on outstanding academic record, extracurricular activities and creativity. Applications will be accepted through Friday, June 14.
"AbbVie is proud to be able to provide this scholarship to exceptional students living with CF," said Jim Hynd, divisional vice president, Cardiovascular Care, Metabolics and GI Care, AbbVie. "For more than 20 years, we have been inspired by the CF scholars who continually demonstrate that it is possible to achieve personal and academic success while living with a chronic disease."
Later this year, in honor of the 21st year of the scholarship program, the forty AbbVie CF Scholarship recipients will have the opportunity to compete for one of two Thriving Student Scholarships (based on level of study) resulting in a total scholarship award of $21,000 each.
It is not necessary for scholarship applicants to have taken, currently take, or intend to take in the future, any medicine or product marketed by AbbVie and this is not a consideration in the selection criteria. More information about the AbbVie CF Scholarship criteria and application can be found at www.AbbVieCFScholarship.com.
About Cystic Fibrosis
Approximately 30,000 children and adults in the United States are living with CF, an inherited chronic disease that affects the lungs and digestive systems. More than 70 percent of people with CF are diagnosed by age two. Today, more than 45 percent of people living with CF are aged 18 or older. In patients with CF, a thick, sticky mucus is produced in certain organs throughout the body, most commonly the lungs and digestive system. The mucus build-up in the lungs can cause difficulty breathing and may lead to life-threatening lung infections. In the digestive system, the thick mucus may prevent proper food digestion.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.